Business
National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims
A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) for failure to comply with its recommendation to discontinue or modify express once-a-year dosing claims for its Bravecto® Quantum injectable flea and tick treatment for dogs.New York, NY, May 20, 2026 (GLOBE NEWSWIRE) -- A panel of the National Adv
About this update from Merck & Company, Inc.
[{"type":"image","caption":"","headline":"National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims","size":{"original":{"width":152,"height":69,"url":"https://media.zenfs.com/en/globenewswire.com/465d9e6e55ec2297f2e3d8f1a7f346fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UZceHdX8bioN5cZHBGfYSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTk1/https://media.zenfs.com/en/globenewswire.com/465d9e6e55ec2297f2e3d8f1a7f346fb","width":152,"height":69},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/UZceHdX8bioN5cZHBGfYSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTk1/https://media.zenfs.com/en/globenewswire.com/465d9e6e55ec2297f2e3d8f1a7f346fb","width":152,"height":69}}},{"type":"text","content":"A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) for failure to comply with its recommendation to discontinue or modify express once-a-year dosing claims for its Bravecto® Quantum injectable flea and tick treatment for dogs.","length":426,"tagName":"p"},{"type":"text","content":"New York, NY, May 20, 2026 (GLOBE NEWSWIRE) -- A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) for failure to comply with its recommendation to discontinue or modify express once-a-year dosing claims for its Bravecto® Quantum injectable flea and tick treatment for dogs.","length":473,"tagName":"p"},{"type":"text","content":"Merck Animal Health appealed the National Advertising Division’s (NAD) (Case #7519) recommendation that Merck Animal Health discontinue or modify its express Bravecto Quantum once-a-year dosing claims, which included claims that a "quick injection" provides "1 full year* of flea and tick protection for dogs" and offers "365 days of protection, all in one dose." The challenger in the case is Elanco Animal Health, Inc.","length":450,"tagName":"p"},{"type":"text","content":"The NARB panel found that Merck’s express once-a-year dosing claims are inaccurate and misleading. While the first FDA-approved i...